299 related articles for article (PubMed ID: 17276556)
1. Mimotope vaccines for cancer immunotherapy.
Sharav T; Wiesmüller KH; Walden P
Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope.
Tumenjargal S; Gellrich S; Linnemann T; Muche JM; Lukowsky A; Audring H; Wiesmüller KH; Sterry W; Walden P
Eur J Immunol; 2003 Nov; 33(11):3175-85. PubMed ID: 14579286
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
5. Synthetic antigenic peptides as a new strategy for immunotherapy of cancer.
Appella E; Loftus DJ; Sakaguchi K; Sette A; Celis E
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):177-84. PubMed ID: 9346850
[TBL] [Abstract][Full Text] [Related]
6. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
[TBL] [Abstract][Full Text] [Related]
7. Peptide vaccines and peptide libraries.
Wiesmüller KH; Fleckenstein B; Jung G
Biol Chem; 2001 Apr; 382(4):571-9. PubMed ID: 11405221
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
9. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
10. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
11. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. T-cell epitope analogues from carcinoembryonic antigen for vaccination against cancer: WO2009002418.
Hallermalm K
Expert Opin Ther Pat; 2009 Nov; 19(11):1635-7. PubMed ID: 19566377
[TBL] [Abstract][Full Text] [Related]
14. Taming cancer by inducing immunity via dendritic cells.
Palucka AK; Ueno H; Fay JW; Banchereau J
Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of the hTERT540-548 peptide in cancer.
Wenandy L; Sørensen RB; Sengeløv L; Svane IM; thor Straten P; Andersen MH
Clin Cancer Res; 2008 Jan; 14(1):4-7. PubMed ID: 18172245
[TBL] [Abstract][Full Text] [Related]
16. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
17. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
18. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
19. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
20. Activation or frustration of anti-tumor responses by T-cell-based immune modulation.
Toes RE; Schoenberger SP; van der Voort EI; Kast WM; Hoeben RC; Melief CJ; Offringa R
Semin Immunol; 1997 Oct; 9(5):323-7. PubMed ID: 9327527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
